Researchers evaluated protection conferred by a single COVID-19 mRNA vaccine dose vs a 2-dose series in the setting of high preexisting SARS-CoV-2 immunity.

Dr Patrick Moore, the study's chief investigator and the National Institute for Health and Care Research (NIHR) director in ...

Deep-pocketed investors have adopted a bearish approach towards Capricor Therapeutics CAPR, and it's something market players ...

Participants, about 80% of whom had a previous COVID-19 infection, received a median of four COVID-19 vaccine doses. “In this ...

During the COVID pandemic, many of us received multiple mRNA vaccines. New work by researchers at the VIB-UGent Center for ...

During the COVID pandemic, many of us have received multiple mRNA vaccines. New work by researchers at the VIB-UGent Center ...

The FDA approves Pfizer's RSV vaccine, Abrysvo, for adults aged 18-59 years with increased risk of the disease.

A trial in the UK will see a norovirus given to patients with the Health Secretary hoping it will cut the “burden on the NHS”.

The FDA expanded the approval of the bivalent RSV prefusion F (RSVpreF) vaccine (Abrysvo) to include the prevention of lower ...

A new vaccine against the winter vomiting bug, norovirus, is being tested on volunteers after preliminary findings indicated ...

COVID-19 vaccination is associated with a reduced risk for most CV events, but with slightly increased risks for extrasystoles and transient ischemic attack, as well as myocarditis and pericarditis ...

COVID-19 2024–2025 vaccines are recommended for everyone aged 6 months and older, with vaccines targeting the JN.1 and KP.2 strains of SARS-CoV-2.